As headache neurologists, it is a common experience to meet a new patient with a headache that began on a particular day several months or years ago, and which has, unfortunately, been present ever since. This presentation may be encountered even more often in pediatric headache clinics, as new daily persistent headache (NDPH) may have a predilection for onset in adolescence. 1 The International Classification of Headache Disorders, 3rd edition, diagnostic criteria for NDPH specify that the headache has a "distinct and clearly remembered onset," becomes continuous within 24 hours of starting, has been present for a minimum of 3 months, and is not better ascribed to another primary or secondary headache disorder. 2 The headache phenotype may resemble chronic migraine or chronic tension-type headache. Although prospective studies on NDPH are limited, it is typical for the headache to last for years, no matter what types of treatment are given, 3 at least among patients coming for care in a subspecialty headache clinic. To the lay person, and even to many medical professionals, the notion that a person could have 1 spontaneous, continuous headache for years may seem preposterous. As an invisible illness, with no demonstrable laboratory or imaging biomarker, NDPH is a setup for patients to experience social stigma and can be truly life shattering.Despite its effect, we know shockingly little about NDPH. For example, what are its causes? NDPH is a syndrome with presumably multiple possible etiologies and inciting factors, 4 and there is no consensus on which secondary causes of headache must be ruled out before diagnosis. For those who have a preexisting history of infrequent migraine, is it simply a migraine attack that started in some unusual way or for some reason failed to turn off? For those in whom NDPH began in the setting of a systemic viral illness, such as Epstein-Barr virus or COVID-19 infection, 5-7 is an inflammatory or autoimmune trigger responsible? It is unclear whether focusing on the inciting event at NDPH onset, or on the NDPH symptoms (ie, the phenotype), may provide the most useful clues toward clarifying the underlying pathophysiology and effective treatments for this condition. A common practice is for clinicians to treat the headache phenotype, ie, to use migraine therapies if the NDPH phenotype is migrainous, and tension-type headache therapies (which, practically speaking, may overlap with migraine therapies) if it is featureless. However, without biomarkers, neuroimaging data, an understanding of underlying pathophysiology, or any randomized clinical trials to inform treatment decisions, we are practicing in an evidence-free zone.Experts may not even agree as to what it means for a headache to be new. For example, if before the onset of the continuous headache, the patient experienced mi-